Envisia Therapeutics Names Eric Linsley Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Envisia Therapeutics today announced that it has named Eric Linsley as the Company's Chief Financial Officer. Prior to Envisia, Mr. Linsley was a managing partner at Pappas Ventures in Durham, NC where he was directly responsible for investments that led to several very successful acquisitions and public offerings. He brings with him more than 20 years of experience and a proven track record of finance and life science investment expertise.

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.